Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CVS beats Q4 earnings and revenue estimates, but higher costs squeeze margins. Shares slip pre-market despite upbeat 2026 EPS guidance.
CVS Health Corporation (CVS) Q4 2025 Earnings Call Transcript
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS Health Corp (NYSE:CVS) on Tuesday reported stronger-than-expected fourth-quarter revenue and adjusted earnings, driven by growth across its pharmacy, health services, and insurance businesses. The US pharmacy chain and health insurer said fourth-quarter revenue rose 8.2% to $105.7 billion, topping analysts' expectations of $103.6 billion.
CVS Health (CVS) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $1.19 per share a year ago.
CVS Health (NYSE: CVS) delivered a solid revenue beat in Q4 2025, though adjusted earnings declined year-over-year despite exceeding Wall Street expectations.
CVS Health earnings came in ahead of analyst forecasts but the company is concerned about Medicare rates.
The healthcare giant saw its revenue jump 8% in the fourth quarter
CVS Health reported earnings that beat analysts' expectations and kept its 2026 profit guidance unchanged, results that may soothe investors spooked by continued turmoil in the health-insurance sector.